Last Updated: November 8, 2026

CLINICAL TRIALS PROFILE FOR INSULIN DETEMIR

« Back to Dashboard

All Clinical Trials for insulin detemir

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00095082 ↗	Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes	Completed	Novo Nordisk A/S	Phase 3	2004-09-01	This trial is conducted in Europe and the United States of America (USA). The purpose of this study is to test whether insulin detemir is a safe and at least as effective alternative to insulin glargine for the control of blood glucose in basal/bolus therapy in patients with type I diabetes.
NCT00097084 ↗	Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes	Completed	Novo Nordisk A/S	Phase 3	2004-09-01	This trial is conducted in Europe and the United States of America (USA). The purpose of this study is to test whether insulin detemir is a safe and at least as effective alternative to insulin glargine for the control of blood glucose in basal/bolus therapy in patients with type 2 diabetes.
NCT00104182 ↗	Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes	Completed	Novo Nordisk A/S	Phase 3	2005-02-01	This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare the use of Insulin Detemir once a day (morning or evening) to NPH Insulin once a day (evening) when added to treatment with oral antidiabetic drugs in patients with Type 2 diabetes.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for insulin detemir

Condition Name

Chart
Table

Condition Name for insulin detemir
Intervention	Trials
Diabetes	122
Diabetes Mellitus, Type 2	88
Diabetes Mellitus, Type 1	59
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for insulin detemir
Intervention	Trials
Diabetes Mellitus	163
Diabetes Mellitus, Type 2	111
Diabetes Mellitus, Type 1	72
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for insulin detemir

Trials by Country

Map
Table

Trials by Country for insulin detemir
Location	Trials
United States	562
Canada	57
United Kingdom	38
Germany	32
France	31
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for insulin detemir
Location	Trials
Texas	32
California	30
Georgia	24
Florida	23
New York	22
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for insulin detemir

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for insulin detemir
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	1
PHASE1	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for insulin detemir
Clinical Trial Phase	Trials
Completed	164
Terminated	12
Unknown status	7
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for insulin detemir

Sponsor Name

Chart
Table

Sponsor Name for insulin detemir
Sponsor	Trials
Novo Nordisk A/S	143
Sanofi	5
University of Texas Southwestern Medical Center	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for insulin detemir
Sponsor	Trials
Industry	169
Other	92
NIH	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.